tiprankstipranks
Kura Oncology price target lowered to $10 from $18 at Scotiabank
The Fly

Kura Oncology price target lowered to $10 from $18 at Scotiabank

Scotiabank lowered the firm’s price target on Kura Oncology (KURA) to $10 from $18 and keeps a Sector Perform rating on the shares. The firm adjusted its price target on the stock based on its revised market share estimates for revumenib in relapsed/refractory KMT2Ar acute lymphoblastic leukemia and front-line acute leukemia treatment settings, the analyst tells investors.

Stay Ahead of the Market:

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App